Biotech Values

[jmkobers]

I agree that TEVA claiming that copying copaxone is impossible makes sense, but I strongly disagree that there is any real incentive to claim their generic lovenox application is ready to be approved when it isn't. MNTA knew when they were close so it's reasonable to assume TEVA would know as well.

Whether MNTA's share price is 10 or 30 isn't really relevant. MNTA is going to go forward with copaxone regardless of the market's valuation of them. If you agree on this point, then help me understand, why would TEVA mislead/lie about lovenox?